Duopharma Biotech Reports Higher 4Q 2021 Revenue Amidst Challenge of Higher Costs
● 4Q revenue grows 8.5% to RM145.44 million compared to previous corresponding quarter
● Second interim dividend of 1.8 sen per share
● New and extended public sector supply contracts, potential tax savings to bolster future earnings